Genentech Corporation is withdrawing its psoriasis drug Raptiva from the U.S. market after the U.S. Food & Drug Administration (FDA) warned that the drug has been linked to brain disease. So, what is Raptiva, why was it recalled and most importantly – what should you do if you’ve taken it?

What is Raptiva?

Raptiva, also known as efalizumab and manufactured by Genentecch, is an injectable immunosuppressant that treats plaque psoriasis – which is a chronic autoimmune disease that affects the skin and joints. While the drug had been recommended to be used weekly in adults older than 18 years, research suggests that prolonged use of Raptiva in those younger than 18 years old could lead to a permanently suppressed immune system. Genentech has recalled the drug.

Why was Raptiva recalled?

The FDA reported that Raptiva, which was approved for use in 2003, has been linked to several life-threatening infections, including bacterial sepsis, viral meningitis and invasive fungal disease. It has also been linked to a rare brain disease known as progressive multifocal leukoencephalopathy (PML). Symptoms of PML include changes in vision, difficulty speaking, loss of coordination, personality changes and general weakness. It typically occurs in people with AIDS (acquired immune deficiency syndrome) or people undergoing immunosuppressive therapies.

What should you do if you’ve taken Raptiva?

According to an FDA press release, Raptiva will no longer be available in the United States after June 8th 2009. The Administration says that, “Prescribers are being asked not to initiate Raptiva treatment for any new patients. Prescribers should immediately begin discussing with patients currently using Raptiva how to transition to alternative therapies. The FDA strongly recommends that patients work with their health care professional to transition to alternative therapies for psoriasis.”

If you’ve been injured by Raptiva, contact an experienced products liability attorney whose practice focuses in the area of drug litigation to discuss your situation and evaluate your options.